Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 May;77(10):1645–1652. doi: 10.1038/bjc.1998.270

Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.

J Ma 1, M Maliepaard 1, K Nooter 1, W J Loos 1, H J Kolker 1, J Verweij 1, G Stoter 1, J H Schellens 1
PMCID: PMC2150067  PMID: 9635842

Abstract

In order to unravel possible mechanisms of clinical resistance to topoisomerase I inhibitors, we developed a topotecan-resistant human IGROV-1 ovarian cancer cell line, denoted IGROV(T100r), by stepwise increased exposure to topotecan (TPT). The IGROV(T100r) cell line was 29-fold resistant to TPT and strongly cross-resistant to SN-38 (51-fold). However, the IGROV(T100r) showed only threefold resistance to camptothecin (CPT). Remarkably, this cell line was 32-fold resistant to mitoxantrone, whereas no significant cross-resistance against other cytostatic drugs was observed. No differences in topoisomerase I protein levels and catalytic activity as well as topoisomerase I cleavable complex stabilization by CPT in the IGROV-1 and IGROV(T100r) cell lines were observed, indicating that resistance in the IGROV(T100r) cell line was not related to topoisomerase I-related changes. However, resistance in the resistant IGROV(T100r) cell line to TPT and SN-38 was accompanied by decreased accumulation of the drugs to approximately 15% and 36% of that obtained in IGROV-1 respectively. No reduced accumulation was observed for CPT. Notably, accumulation of TPT in the IGROV-1 cell line decreased under energy-deprived conditions, whereas the accumulation in the IGROV(T100r) cell line increased under these energy-deprived conditions. The efflux of TPT at 37 degrees C was very rapid in the IGROV-1 as well as the IGROV(T100r) cell line, resulting in 90% efflux within 20 min. Importantly, the efflux rates of TPT in the IGROV-1 and IGROV(T100r) cell lines were not significantly different and were shown to be independent on P-glycoprotein (P-gp) or multidrug resistance-associated protein (MRP). These results strongly suggest that the resistance of the IGROV(T100r) cell line to TPT and SN-38 is mainly caused by reduced accumulation. The reduced accumulation appears to be mediated by a novel mechanism, probably related to impaired energy-dependent uptake of these topoisomerase I drugs.

Full text

PDF
1649

Images in this article

1648Figure 2
on p.1648
1649Figure 3
on p.1649
1649Figure 4
on p.1649
1649Figure 5
on p.1649

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andoh T., Ishii K., Suzuki Y., Ikegami Y., Kusunoki Y., Takemoto Y., Okada K. Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci U S A. 1987 Aug;84(16):5565–5569. doi: 10.1073/pnas.84.16.5565. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beijnen J. H., Smith B. R., Keijer W. J., van Gijn R., ten Bokkel Huinink W. W., Vlasveld L. T., Rodenhuis S., Underberg W. J. High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma. J Pharm Biomed Anal. 1990;8(8-12):789–794. doi: 10.1016/0731-7085(90)80122-6. [DOI] [PubMed] [Google Scholar]
  3. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  4. Conti J. A., Kemeny N. E., Saltz L. B., Huang Y., Tong W. P., Chou T. C., Sun M., Pulliam S., Gonzalez C. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996 Mar;14(3):709–715. doi: 10.1200/JCO.1996.14.3.709. [DOI] [PubMed] [Google Scholar]
  5. Eng W. K., McCabe F. L., Tan K. B., Mattern M. R., Hofmann G. A., Woessner R. D., Hertzberg R. P., Johnson R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 1990 Oct;38(4):471–480. [PubMed] [Google Scholar]
  6. Flens M. J., Izquierdo M. A., Scheffer G. L., Fritz J. M., Meijer C. J., Scheper R. J., Zaman G. J. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 1994 Sep 1;54(17):4557–4563. [PubMed] [Google Scholar]
  7. Fujimori A., Harker W. G., Kohlhagen G., Hoki Y., Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin. Cancer Res. 1995 Mar 15;55(6):1339–1346. [PubMed] [Google Scholar]
  8. Gallo R. C., Whang-Peng J., Adamson R. H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J Natl Cancer Inst. 1971 Apr;46(4):789–795. [PubMed] [Google Scholar]
  9. Garg L. C., DiAngelo S., Jacob S. T. Role of DNA topoisomerase I in the transcription of supercoiled rRNA gene. Proc Natl Acad Sci U S A. 1987 May;84(10):3185–3188. doi: 10.1073/pnas.84.10.3185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Giovanella B. C., Stehlin J. S., Wall M. E., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts. Science. 1989 Nov 24;246(4933):1046–1048. doi: 10.1126/science.2555920. [DOI] [PubMed] [Google Scholar]
  11. Grogan T., Dalton W., Rybski J., Spier C., Meltzer P., Richter L., Gleason M., Pindur J., Cline A., Scheper R. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. Lab Invest. 1990 Dec;63(6):815–824. [PubMed] [Google Scholar]
  12. Hasegawa S., Abe T., Naito S., Kotoh S., Kumazawa J., Hipfner D. R., Deeley R. G., Cole S. P., Kuwano M. Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer. 1995 May;71(5):907–913. doi: 10.1038/bjc.1995.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donehower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 1992 Apr 15;52(8):2268–2278. [PubMed] [Google Scholar]
  14. Hsiang Y. H., Hertzberg R., Hecht S., Liu L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985 Nov 25;260(27):14873–14878. [PubMed] [Google Scholar]
  15. Hsiang Y. H., Lihou M. G., Liu L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 1989 Sep 15;49(18):5077–5082. [PubMed] [Google Scholar]
  16. Kanzawa F., Sugimoto Y., Minato K., Kasahara K., Bungo M., Nakagawa K., Fujiwara Y., Liu L. F., Saijo N. Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 1990 Sep 15;50(18):5919–5924. [PubMed] [Google Scholar]
  17. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  18. Liu L. F., Miller K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3487–3491. doi: 10.1073/pnas.78.6.3487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Loos W. J., Stoter G., Verweij J., Schellens J. H. Sensitive high-performance liquid chromatographic fluorescence assay for the quantitation of topotecan (SKF 104864-A) and its lactone ring-opened product (hydroxy acid) in human plasma and urine. J Chromatogr B Biomed Appl. 1996 Apr 12;678(2):309–315. doi: 10.1016/0378-4347(95)00529-3. [DOI] [PubMed] [Google Scholar]
  20. Madelaine I., Prost S., Naudin A., Riou G., Lavelle F., Riou J. F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol. 1993 Jan 26;45(2):339–348. doi: 10.1016/0006-2952(93)90069-9. [DOI] [PubMed] [Google Scholar]
  21. Nooter K., Westerman A. M., Flens M. J., Zaman G. J., Scheper R. J., van Wingerden K. E., Burger H., Oostrum R., Boersma T., Sonneveld P. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res. 1995 Nov;1(11):1301–1310. [PubMed] [Google Scholar]
  22. Pantazis P., Mendoza J., DeJesus A., Early J., Shaw M., Giovanella B. C. Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anticancer Drugs. 1994 Aug;5(4):473–479. doi: 10.1097/00001813-199408000-00014. [DOI] [PubMed] [Google Scholar]
  23. Potmesil M. Camptothecins: from bench research to hospital wards. Cancer Res. 1994 Mar 15;54(6):1431–1439. [PubMed] [Google Scholar]
  24. Rowinsky E. K., Adjei A., Donehower R. C., Gore S. D., Jones R. J., Burke P. J., Cheng Y. C., Grochow L. B., Kaufmann S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol. 1994 Oct;12(10):2193–2203. doi: 10.1200/JCO.1994.12.10.2193. [DOI] [PubMed] [Google Scholar]
  25. Rowinsky E. K., Grochow L. B., Hendricks C. B., Ettinger D. S., Forastiere A. A., Hurowitz L. A., McGuire W. P., Sartorius S. E., Lubejko B. G., Kaufmann S. H. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol. 1992 Apr;10(4):647–656. doi: 10.1200/JCO.1992.10.4.647. [DOI] [PubMed] [Google Scholar]
  26. Sinha B. K. Topoisomerase inhibitors. A review of their therapeutic potential in cancer. Drugs. 1995 Jan;49(1):11–19. doi: 10.2165/00003495-199549010-00002. [DOI] [PubMed] [Google Scholar]
  27. Sirotnak F. M., Yang C. H., Mines L. S., Oribé E., Biedler J. L. Markedly altered membrane transport and intracellular binding of vincristine in multidrug-resistant Chinese hamster cells selected for resistance to vinca alkaloids. J Cell Physiol. 1986 Feb;126(2):266–274. doi: 10.1002/jcp.1041260217. [DOI] [PubMed] [Google Scholar]
  28. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., Warren J. T., Bokesch H., Kenney S., Boyd M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst. 1990 Jul 4;82(13):1107–1112. doi: 10.1093/jnci/82.13.1107. [DOI] [PubMed] [Google Scholar]
  29. Slichenmyer W. J., Rowinsky E. K., Donehower R. C., Kaufmann S. H. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst. 1993 Feb 17;85(4):271–291. doi: 10.1093/jnci/85.4.271. [DOI] [PubMed] [Google Scholar]
  30. Sonneveld P., Durie B. G., Lokhorst H. M., Marie J. P., Solbu G., Suciu S., Zittoun R., Löwenberg B., Nooter K. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet. 1992 Aug 1;340(8814):255–259. doi: 10.1016/0140-6736(92)92353-h. [DOI] [PubMed] [Google Scholar]
  31. Sorensen M., Sehested M., Jensen P. B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 1995 Aug;72(2):399–404. doi: 10.1038/bjc.1995.345. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 1990 Nov 1;50(21):6925–6930. [PubMed] [Google Scholar]
  33. Tanizawa A., Fujimori A., Fujimori Y., Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 1994 Jun 1;86(11):836–842. doi: 10.1093/jnci/86.11.836. [DOI] [PubMed] [Google Scholar]
  34. Versantvoort C. H., Broxterman H. J., Bagrij T., Scheper R. J., Twentyman P. R. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer. 1995 Jul;72(1):82–89. doi: 10.1038/bjc.1995.281. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Versantvoort C. H., Broxterman H. J., Pinedo H. M., de Vries E. G., Feller N., Kuiper C. M., Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 1992 Jan 1;52(1):17–23. [PubMed] [Google Scholar]
  36. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 1985;54:665–697. doi: 10.1146/annurev.bi.54.070185.003313. [DOI] [PubMed] [Google Scholar]
  37. Yang C. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 1995 Sep 15;55(18):4004–4009. [PubMed] [Google Scholar]
  38. Zaman G. J., Lankelma J., van Tellingen O., Beijnen J., Dekker H., Paulusma C., Oude Elferink R. P., Baas F., Borst P. Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7690–7694. doi: 10.1073/pnas.92.17.7690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Zaman G. J., Versantvoort C. H., Smit J. J., Eijdems E. W., de Haas M., Smith A. J., Broxterman H. J., Mulder N. H., de Vries E. G., Baas F. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 1993 Apr 15;53(8):1747–1750. [PubMed] [Google Scholar]
  40. van der Zee A. G., Hollema H., de Jong S., Boonstra H., Gouw A., Willemse P. H., Zijlstra J. G., de Vries E. G. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res. 1991 Nov 1;51(21):5915–5920. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES